ATE490244T1 - Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren - Google Patents

Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren

Info

Publication number
ATE490244T1
ATE490244T1 AT04704951T AT04704951T ATE490244T1 AT E490244 T1 ATE490244 T1 AT E490244T1 AT 04704951 T AT04704951 T AT 04704951T AT 04704951 T AT04704951 T AT 04704951T AT E490244 T1 ATE490244 T1 AT E490244T1
Authority
AT
Austria
Prior art keywords
compounds
methods
compositions containing
substituted pyrazoles
pyrazoles
Prior art date
Application number
AT04704951T
Other languages
German (de)
English (en)
Inventor
Emma Parmee
Subharekha Raghavan
Teresa Beeson
Dong-Ming Shen
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32850762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE490244(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE490244T1 publication Critical patent/ATE490244T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04704951T 2003-01-27 2004-01-23 Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren ATE490244T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44282803P 2003-01-27 2003-01-27
PCT/US2004/001927 WO2004069158A2 (en) 2003-01-27 2004-01-23 Substituted pyrazoles, compositions containing such compounds and methods of use

Publications (1)

Publication Number Publication Date
ATE490244T1 true ATE490244T1 (de) 2010-12-15

Family

ID=32850762

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04704951T ATE490244T1 (de) 2003-01-27 2004-01-23 Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren

Country Status (8)

Country Link
US (2) US7572922B2 (cg-RX-API-DMAC7.html)
EP (1) EP1590336B1 (cg-RX-API-DMAC7.html)
JP (2) JP4560035B2 (cg-RX-API-DMAC7.html)
AT (1) ATE490244T1 (cg-RX-API-DMAC7.html)
AU (2) AU2004210127B2 (cg-RX-API-DMAC7.html)
CA (1) CA2513102C (cg-RX-API-DMAC7.html)
DE (1) DE602004030318D1 (cg-RX-API-DMAC7.html)
WO (1) WO2004069158A2 (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004210127B2 (en) * 2003-01-27 2009-10-01 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
US7589116B2 (en) 2003-04-03 2009-09-15 Merck & Co. Inc. Biaryl substituted pyrazoles as sodium channel blockers
NZ551405A (en) * 2004-06-04 2009-06-26 Merck & Co Inc Pyrazole derivatives, compositions containing such compounds and methods of use
CN1980665A (zh) * 2004-07-07 2007-06-13 默克公司 吡唑酰胺衍生物，包含这些化合物的组合物和使用方法
WO2006014618A2 (en) * 2004-07-22 2006-02-09 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
US8318760B2 (en) 2005-03-21 2012-11-27 Merck Sharp & Dohme Corp. Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use
EP1896436A2 (en) 2005-05-11 2008-03-12 Takeda San Diego, Inc. Histone deacetylase inhibitors
BRPI0612287A8 (pt) 2005-06-27 2019-01-22 Exelixis Inc composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear
CN101300232A (zh) * 2005-07-26 2008-11-05 默克公司 合成取代的吡唑的方法
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
US7989472B2 (en) 2006-03-23 2011-08-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EP2418202B1 (en) 2006-03-31 2014-01-29 Novartis AG (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors
US7935713B2 (en) 2006-05-16 2011-05-03 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
KR20090094125A (ko) 2006-12-08 2009-09-03 엑셀리시스, 인코포레이티드 Ｌｘｒ 및 ｆｘｒ 조절자
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
KR20200123866A (ko) 2007-02-09 2020-10-30 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
SI2178858T1 (sl) * 2007-08-02 2012-03-30 Recordati Ireland Ltd Nove heterociklične spojine kot mGlu antagonisti
US8232413B2 (en) * 2007-09-12 2012-07-31 Merck Sharp & Dohme Corp. Process for the production of a crystalline glucagon receptor antagonist compound
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
US8309580B2 (en) 2007-11-01 2012-11-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2009082761A1 (en) 2007-12-26 2009-07-02 Elster Electricity, Llc. Optimized data collection in a wireless fixed network metering system
BRPI0912245A2 (pt) * 2008-03-05 2019-09-24 Takeda Pharmaceuticals Co composto, prodroga, medicamento, métodos de suprimir produção de açúcar em um mamífero e para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso do composto
WO2009140342A1 (en) * 2008-05-16 2009-11-19 Schering Corporation Glucagon receptor antagonists, compositions, and methods for their use
KR20100122513A (ko) 2008-07-17 2010-11-22 아사히 가세이 파마 가부시키가이샤 질소 함유 복소환 화합물
PT2799428T (pt) 2008-08-13 2017-02-17 Metabasis Therapeutics Inc Antagonistas de glicagina
EP2346830B1 (en) * 2008-09-15 2015-05-13 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
JP2012504630A (ja) * 2008-10-03 2012-02-23 シェーリング コーポレイション グルカゴン受容体アンタゴニストとしてのスピロイミダゾロン誘導体
CN102171199A (zh) * 2008-10-10 2011-08-31 隆萨有限公司 制备2-烷基-3-芳酰基-5-硝基-苯并呋喃类的方法
US8324384B2 (en) 2009-02-12 2012-12-04 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8318667B2 (en) 2009-02-25 2012-11-27 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010144664A1 (en) * 2009-06-12 2010-12-16 Schering Corporation Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
US8735604B2 (en) 2009-09-22 2014-05-27 Merck Sharp & Dohme Corp. Pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
EP2568812B1 (en) * 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
EP2588465B1 (en) * 2010-06-30 2017-01-25 Ironwood Pharmaceuticals, Inc. Sgc stimulators
CN107266433A (zh) 2010-11-09 2017-10-20 铁木医药有限公司 sGC刺激剂
NZ611529A (en) 2010-12-23 2015-06-26 Pfizer Glucagon receptor modulators
WO2012107850A1 (en) 2011-02-08 2012-08-16 Pfizer Inc. Glucagon receptor modulator
US8927577B2 (en) 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
CN106117194A (zh) * 2011-12-27 2016-11-16 铁木医药有限公司 可用作sgc刺激剂的2‑苄基、3‑(嘧啶‑2‑基)取代的吡唑类
EP3065736B1 (en) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
TWI757332B (zh) * 2016-09-06 2022-03-11 比利時商健生藥品公司 使用作為升糖素受體拮抗劑之吲唑衍生物
TW201811752A (zh) * 2016-09-06 2018-04-01 比利時商健生藥品公司 用作升糖素受體拮抗劑之吲唑衍生物
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists
EP4452253A4 (en) 2021-12-23 2026-04-15 The Katholieke Univ Leuven 2-PYRAZOLE, ANILINES AND RELATED ANALOGUES TO INHIBIT YAP/TAZ-TEAD
WO2025034531A1 (en) * 2023-08-04 2025-02-13 The University Of Vermont And State Agricultural College Small molecule allosteric modulator to pac1 receptor and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9303993D0 (en) 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
BE1009189A3 (fr) * 1995-03-14 1996-12-03 Solvay Procede pour la fabrication d'un corps creux.
AU702887B2 (en) 1995-10-31 1999-03-11 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
AR008789A1 (es) * 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5776954A (en) 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
WO1998021957A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles, compositions containing such compounds and methods of use
EP0959886A4 (en) 1996-11-20 2001-05-02 Merck & Co Inc TRIARYL SUBSTITUTED IMIDAZOLES AS GLUCAGON ANTAGONISTS
EP0959885A4 (en) 1996-11-20 2002-07-17 Merck & Co Inc TRIARYL SUBSTITUTED IMIDAZOLES AND METHODS OF USE
DE69719544T2 (de) * 1996-12-12 2003-11-06 Banyu Pharmaceutical Co., Ltd. Pyrazolderivate
EE200300169A (et) 1997-04-18 2003-06-16 G.D. Searle & Co. Tsüklooksügenaas-2 inhibiitorite kasutamise meetod südame-veresoonkonna haiguste ärahoidmiseks
US6613942B1 (en) * 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
EP1024134A4 (en) * 1997-10-09 2003-05-14 Ono Pharmaceutical Co DERIVATIVES OF AMINOBUTANIC ACID
IL136711A0 (en) 1997-12-19 2001-06-14 Amgen Inc Substituted pyridine and pyridazine compounds and their pharmaceutical use
GEP20033045B (en) 1998-09-17 2003-08-25 Bristol Myers Squibb Co Method for Treating Diabetes
DE60023492T2 (de) 1999-05-17 2006-07-20 Novo Nordisk A/S Glucagon antagonisten/inverse agonisten
US6503949B1 (en) * 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
JP2003506443A (ja) * 1999-08-10 2003-02-18 バイエルクロップサイエンス株式会社 除草性テトラゾリノン誘導体
IL149493A0 (en) * 1999-11-10 2002-11-10 Takeda Chemical Industries Ltd 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
HUP0301501A2 (hu) 2000-06-23 2003-08-28 Novo Nordisk A/S Glükagon antaagonista/inverz agonista vegyületek, ezeket tartalmazó gyógyászati készítmények, valamint a vegyületek alkalmazása gyógyászati készítmények előállítására
US6562807B2 (en) * 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU7705601A (en) 2000-07-25 2002-02-05 Merck & Co Inc N-substituted indoles useful in the treatment of diabetes
AU2002223501A1 (en) 2000-11-17 2002-05-27 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
ITMI20010733A1 (it) * 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
US6762318B2 (en) * 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US6881746B2 (en) * 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
JP2005511683A (ja) 2001-12-03 2005-04-28 ノボ　ノルディスク　アクティーゼルスカブ 新規なグルカゴンアンタゴニスト
AU2002351730A1 (en) 2001-12-19 2003-06-30 Novo Nordisk A/S Glucagon receptor antagonists/inverse agonists
AU2002347022A1 (en) 2001-12-20 2003-07-09 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
WO2003064404A1 (en) 2002-02-01 2003-08-07 Dainippon Pharmaceutical Co., Ltd. 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
EP1519723A1 (en) 2002-06-27 2005-04-06 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
ATE505223T1 (de) 2002-07-19 2011-04-15 Baxter Int System für die peritonealdialyse
EP1400243A1 (en) 2002-09-19 2004-03-24 Tanabe Seiyaku Co., Ltd. Calcium-activated K channel activator
CA2508581A1 (en) 2002-12-04 2004-06-17 Merck & Co., Inc. Spirocyclic ureas, compositions containing such compounds and methods of use
AU2004210127B2 (en) 2003-01-27 2009-10-01 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
EA200501607A1 (ru) 2003-04-14 2006-06-30 ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи Замещённые фенилалкановые кислоты
DE10317108A1 (de) 2003-04-14 2004-11-11 Mutzbauer, Till S., Dr. Dr.med. Transdermal applizierbares Beruhigungs- und Sedierungsmittel
CA2524436A1 (en) 2003-05-09 2004-11-25 Merck & Co., Inc. Benzimidazoles, compositions containing such compounds and methods of use
NZ551405A (en) 2004-06-04 2009-06-26 Merck & Co Inc Pyrazole derivatives, compositions containing such compounds and methods of use
WO2006014618A2 (en) * 2004-07-22 2006-02-09 Merck & Co., Inc. Substituted pyrazoles, compositions containing such compounds and methods of use
AR056574A1 (es) * 2005-10-19 2007-10-10 Merck & Co Inc Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Also Published As

Publication number Publication date
WO2004069158A2 (en) 2004-08-19
CA2513102A1 (en) 2004-08-19
US20090215825A1 (en) 2009-08-27
EP1590336A4 (en) 2008-12-17
US7572922B2 (en) 2009-08-11
JP2006516622A (ja) 2006-07-06
AU2004210127B2 (en) 2009-10-01
EP1590336B1 (en) 2010-12-01
WO2004069158A3 (en) 2005-01-20
US20060084681A1 (en) 2006-04-20
JP5260569B2 (ja) 2013-08-14
AU2004210127A1 (en) 2004-08-19
AU2009240856A1 (en) 2009-12-17
JP4560035B2 (ja) 2010-10-13
EP1590336A2 (en) 2005-11-02
JP2010150267A (ja) 2010-07-08
US7989475B2 (en) 2011-08-02
CA2513102C (en) 2011-03-22
DE602004030318D1 (de) 2011-01-13

Similar Documents

Publication Publication Date Title
ATE490244T1 (de) Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
ATE468853T1 (de) Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
WO2004100875A3 (en) Benzimidazoles, compositions containing such compounds and methods of use
TW200745031A (en) Acyl indoles, compositions containing such compounds and methods of use
WO2004050039A3 (en) Spirocyclic ureas, compositions containing such compounds and methods of use
MY143599A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
ATE532781T1 (de) 5-(acylamino)indazol-derivate als kinase- inhibitoren
MXPA04000707A (es) Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas.
WO2006104826A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
DE602004021472D1 (en) Pyrimiidinverbindungen
ATE449604T1 (de) Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
NO20055516L (no) Kannabinoidreceptorligander og anvendelser derav
ATE384050T1 (de) Benzazepinderivate als histamin-h3-antagonisten
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TW200505903A (en) CGRP receptor antagonists
WO2005013894A3 (en) Benzodiazepine cgrp receptor antagonists
WO2004087649A3 (en) Benodiazepine spirohydantoin cgrp receptor antagonists
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
MXPA04003858A (es) Antagonistas de mch para el tratamiento de obesidad.
DE60234616D1 (de) Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
ATE479655T1 (de) Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
ATE349448T1 (de) Pyrazol-3,4-d-pyrimidinderivate und ihre verwendung bei der behandlung von h.pylori- infektionen
ATE383345T1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
ATE421519T1 (de) Substituierte bizyklische thiophen-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties